Emedastine

CHEMBL594 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
302.4 g/mol
LogP
2.2
Phase
4

This antihistamine works by blocking histamine receptors in the eye to relieve itching caused by allergic conjunctivitis. It is applied as eye drops to provide targeted relief from eye allergy symptoms.

Molekularmasse

302,4000 g/mol

LogP

2,20

TPSA

33,50 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21

InChI

InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3

Molecular Formula

C17H26N4O

HBD / HBA

- / 4

Rotierbare Bindungen

5

Schwere Atome

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This antihistamine works by blocking histamine receptors in the eye to relieve itching caused by allergic conjunctivitis. It is applied as eye drops to provide targeted relief from eye allergy symptoms.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Emedastine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL594. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3219. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.